Compare ONL & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | ELDN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 120.8M |
| IPO Year | N/A | N/A |
| Metric | ONL | ELDN |
|---|---|---|
| Price | $2.02 | $1.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 311.3K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.35 |
| 52 Week High | $4.25 | $4.98 |
| Indicator | ONL | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 39.30 |
| Support Level | $1.97 | $1.47 |
| Resistance Level | $2.13 | $1.76 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 28.21 | 61.40 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.